Zijia Ren

Title: Innovations of Zijia Ren in Blood-Clotting Factor VIII

Introduction

Zijia Ren is a notable inventor based in Kaifeng, China. He has made significant contributions to the field of biotechnology, particularly in the development of blood-clotting factors. With a total of 2 patents, his work focuses on enhancing the efficacy and pharmacokinetics of coagulation factor VIII.

Latest Patents

Zijia Ren's latest patents include innovative approaches to coagulation factor VIII fusion proteins. The first patent, titled "FVIII fusion protein and use thereof," discloses a coagulation factor VIII fusion protein conjugated with polyalkylene glycol. This fusion protein exhibits an extended cyclic half-life, significantly increasing its effectiveness compared to traditional FVIII fusion proteins. The second patent, "Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same," describes a highly glycosylated FVIII fusion protein that maintains biological activity similar to recombinant FVIII while extending its in vivo half-life. This advancement improves both pharmacokinetics and drug efficacy.

Career Highlights

Zijia Ren has worked with prominent companies in the pharmaceutical industry, including Ampsource Biopharma Shanghai Inc. and Furen Pharmaceutical Group Co., Ltd. His experience in these organizations has contributed to his expertise in the development of innovative therapeutic solutions.

Collaborations

Zijia Ren has collaborated with talented individuals such as Wenwen Wang and Qilei Wang. These partnerships have fostered a collaborative environment that enhances the research and development of new biopharmaceuticals.

Conclusion

Zijia Ren's contributions to the field of blood-clotting factors through his innovative patents demonstrate his commitment to advancing medical science. His work not only improves treatment options for patients but also showcases the potential of biotechnology in addressing critical health challenges.